Controversy Over Federal Funding Cuts to mRNA Vaccine Research
Federal cuts of about $500 million to mRNA vaccine development are impacting Vermont's biotech industry, particularly Vernal Biosciences, and raising concerns about future pandemic preparedness and scientific innovation, despite the proven safety and efficacy of mRNA vaccines like those used for COVID-19.